Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.
Horizon Pharma’s late-stage treatment teprotumumab for active thyroid eye disease continues to demonstrate greater efficacy. Two months after releasing positive Phase III data, the company shared additional secondary endpoint data that shows higher levels of patient benefit.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Gilead Sciences Inc.’s experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study, two months after failing another clinical trial.
The Food and Drug Administration approved Merck & Co.’s cancer therapy Keytruda as part of a combination therapy for previously untreated patients with the most common type of kidney cancer.
Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.
Johnson & Johnson reported a first-quarter 2019 profit that exceeded Wall Street expectations on higher sales of the company’s prescription medicines, including a double-digit increase for the psoriasis treatment Stelara, even while facing fierce competition for some other important drugs.
Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.
Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.